Methyl 4-bromo-5-methylbenzo[b]thiophene-2-carboxylate | 154650-17-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: Methyl 4-bromo-5-methylbenzo[b]thiophene-2-carboxylate
• 英文别名: methyl 4-bromo-5-methyl-1-benzothiophene-2-carboxylate
• CAS: 154650-17-6
• 化学式: C₁₁H₉BrO₂S
• 分子量: 285.16
• InChiKey: URFGXZYKTTUIGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  54.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same
  申请人：Yi Kyu Yang

  公开号：US20100004466A1

  公开（公告）日：2010-01-07

  The present invention is related to benzothiophen-2-carbonylguanidine derivatives, a preparation method thereof, and pharmaceutical compositions containing the same. The derivatives have potent inhibitory effect on the sodium/hydrogen exchanger NHE-I, improve the functional recovery of ischemia/reperfusion-induced heart injury in isolated ischemic heart models, and significantly reduce the myocardiac infarct size in in vivo ischemic animal models, thereby showing excellent cardioprotective effects. Also, the derivatives are protective of both neuronal cells and the brain as proven by their protective effects on neuronal cells from necrosis and apoptosis and by their ability to significantly reduce cerebral infarct sizes in in vivo ischemic brain models. The derivatives can be effectively used for the prevention and treatment of ischemic heart diseases such as myocardiac infarction, arrhythmia, angina pectoris and the like, and cerebrovascular diseases such as cerebral stroke and be used as cardioprotective agents to the patients undergoing reperfusion therapy including chemicals such as thrombolytic agents, or surgery such as coronary artery bypass and percutaneous transluminal coronary angioplasty.

  本发明涉及苯并噻吩-2-羧酰基胍衍生物、其制备方法以及含有其的制药组合物。这些衍生物对钠/氢交换NHE-I具有强效的抑制作用，在离体缺血心脏模型中提高了缺血/再灌注所致的心脏损伤的功能恢复，并在体内缺血动物模型中显著减少心肌梗死面积，因此表现出优异的心脏保护作用。此外，这些衍生物通过对神经元细胞的保护作用和在体内缺血脑模型中显著减少脑梗死面积的能力，也能保护神经元和大脑。这些衍生物可有效用于预防和治疗缺血性心脏疾病，如心肌梗死、心律失常、心绞痛等，以及脑血管疾病，如脑卒中，并可用作心脏保护剂，用于接受再灌注治疗的患者，包括使用溶栓剂等化学药物或手术，如冠状动脉旁路移植术和经皮冠状动脉成形术。
• Benzothiophenes and thienothiophenes and related compounds useful, for example, as urokinase inhibitors
  申请人：Eisai Co., Ltd.

  公开号：EP0568289A2

  公开（公告）日：1993-11-03

  Disclosed are benzothiophene and thienothiophene derivatives useful for inhibiting urokinase activiy. Novel components of the formula : wherein R1 is H, NH2, or a halogen ; each R2-R5, independently, is a H, halogen, hydroxy, amino, nitro or organic group, provided that at least one R2-R5 is an organic group which includes 5 carbons or greater, an organic group which contains a sulfur atom or hydroxy, an unsaturated organic group, or a cyclic organic group ; and each R6 and R7, independently, is H or a straight chain alkyl group of between 1 and 6 carbons of the formula : wherein R1 is H, NH2, or a halogen ; each R2-R5, independently, is a H, halogen, hydroxy, amino, nitro, or organic group, provided that at least one of R2-R5 is a group other than H, OH, NO2, CN, a halogen, an alkyl group of between 1 and 4 carbons, an alkoxy group of between 1 and 4 carbons, a haloalkyl group of between 1 and 4 carbons, a haloalkoxy group of between 1 and 4 carbons, an amino group, an amino group substituted with an alkyl group of between 1 and 4 carbons, a nitrile group, or a carboxamidine group, and further provided that no two adjacent R2-R5 groups together form a methylenedioxy group ; and each R6 and R7, independently, is H or a straight chain alkyl group of between 1 and 6 carbons and of the formula : wherein at least one of X, Y, or Z must be C ; at least one of X, Y, or Z must be O, N, or S ; and, if more than one of X, Y, or Z is O, N, or S, then at least one of those groups is N ; R1 is H, NH2, or a halogen ; each R2, R3, or R5, independently, is a H, halogen, or organic group ; and each R6 and R7, independently, is H or a straight chain alkyl group of between 1 and 6 carbons are described.

  公开了可用于抑制尿激酶活性的苯并噻吩和噻吩衍生物。式中的新成分......： 其中 R1 是 H、NH2 或卤素； 每个 R2-R5 分别是 H、卤素、羟基、氨基、硝基或有机基团、 但至少有一个 R2-R5 是包含 5 个碳原子或更多碳原子的有机基团、包含硫原子或羟基的有机基团、不饱和有机基团或环状有机基团；以及 每个 R6 和 R7 分别是 H 或式 1 至 6 碳原子的直链烷基： 其中 R1 是 H、NH2 或卤素； 每个 R2-R5 独立地为 H、卤素、羟基、氨基、硝基或有机基团、 条件是 R2-R5 中至少有一个是除 H、OH、NO2、CN、卤素、1-4 碳原子的烷基、1-4 碳原子的烷氧基、1-4 碳原子的卤代烷基、1-4 碳原子的卤代烷氧基以外的基团、氨基、被 1 至 4 个碳原子的烷基取代的氨基、腈基或羧酰胺基，且相邻两个 R2-R5 基团均不形成亚甲基二氧基......；且 每个 R6 和 R7 分别是 H 或 1 至 6 个碳原子的直链烷基，其式为......： 其中 X、Y 或 Z 中至少有一个必须是 C；X、Y 或 Z 中至少有一个必须是 O、N 或 S；如果 X、Y 或 Z 中不止一个是 O、N 或 S，则这些基团中至少有一个是 N； R1 是 H、NH2 或卤素； 每个 R2、R3 或 R5 分别是 H、卤素或有机基团；以及 每个 R6 和 R7 独立地为 H 或 1 至 6 个碳原子的直链烷基。
• EP1831192A4
  申请人：——

  公开号：EP1831192A4

  公开（公告）日：2009-08-19
• BENZOTHIOPHEN-2-CARBONYLGUANIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

  公开号：EP1831192A1

  公开（公告）日：2007-09-12
• US5340833A
  申请人：——

  公开号：US5340833A

  公开（公告）日：1994-08-23